AADI Stock Overview
A biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aadi Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.30 |
| 52 Week High | US$5.70 |
| 52 Week Low | US$1.21 |
| Beta | 0.37 |
| 11 Month Change | 19.17% |
| 3 Month Change | 45.57% |
| 1 Year Change | -51.27% |
| 33 Year Change | -89.78% |
| 5 Year Change | n/a |
| Change since IPO | -91.15% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop
Jul 03
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?
Jul 02Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)
May 10Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified
Mar 07Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Feb 12Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge
Dec 16Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results
Nov 10Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Oct 03Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Jun 28Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Mar 04Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors
Oct 12A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)
Sep 28Aadi Bioscience: Taking mTOR Inhibition To The Next Level
Sep 21Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Jul 06Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes
Jun 23What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today
Nov 27Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning
Nov 25Shareholder Returns
| AADI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.0% | 2.4% | 2.2% |
| 1Y | -51.3% | 16.2% | 31.7% |
Return vs Industry: AADI underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: AADI underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| AADI volatility | |
|---|---|
| AADI Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AADI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AADI's weekly volatility has decreased from 12% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 53 | Dave Lennon | aadibio.com |
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. Fundamentals Summary
| AADI fundamental statistics | |
|---|---|
| Market cap | US$56.20m |
| Earnings (TTM) | -US$61.69m |
| Revenue (TTM) | US$25.07m |
2.3x
P/S Ratio-0.9x
P/E RatioIs AADI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AADI income statement (TTM) | |
|---|---|
| Revenue | US$25.07m |
| Cost of Revenue | US$52.61m |
| Gross Profit | -US$27.54m |
| Other Expenses | US$34.15m |
| Earnings | -US$61.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.50 |
| Gross Margin | -109.86% |
| Net Profit Margin | -246.06% |
| Debt/Equity Ratio | 0% |
How did AADI perform over the long term?
See historical performance and comparison